TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01880502
Drug: Belviq 10mg
Normalized name: Belviq 10mg Tablet
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belviq 10mg single dose administration
Study: NCT01880502
Drug: Belviq 20mg
Normalized name: lorcaserin hydrochloride Oral Tablet [Belviq]
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belviq 20mg single dose administration
Study: NCT02405364
Drug: Carfilzomib/Lenalidomide/Dexamethasone
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan Consolidation:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Maintenance: Lenalidomide (13 cycles)
Study: NCT00115739
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib 400 mg capsules were administered twice daily with food for 4 week cycles.
Study: NCT01567956
Drug: Propionyl-L-Carnitine
Normalized name: GLYCINE PROPIONYL-L-CARNITINE
DrugBank: Levocarnitine propionate (DB15980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
Study: NCT01168505
Drug: ferric hydroxide saccharate
Normalized name: ferric hydroxide
DrugBank: Ferric sulfate (DB11171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses
Study: NCT05770687
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients started on SGLT2 inhibitors after PCI for AMI
Study: NCT02397954
Drug: Avacincaptad Pegol
Normalized name: Avacincaptad pegol
DrugBank: Avacincaptad pegol (DB15165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with Lucentis, Avastin or Eylea.
Study: NCT02170688
Drug: Isovue 370
Normalized name: IOPAMIDOL 755 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [ISOVUE 370]
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All contrast media doses administered for this study are within the FDA approved dose range in the package insert.
Study: NCT04281706
Drug: Etomidate vs Propofol as induction agent
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients undergoing cardiac surgery were induced with Etomidate according to the standard operating procedure for induction until October 1st, 2013, afterwards a new SOP with Propofol as primary induction agent was introduced. After a washout period of 3 months, Propofol was used as sole induction agent. The rest of the standard operating procedure remained the same.
Study: NCT02466503
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhaled corticosteroid, pMDI
Study: NCT02466503
Drug: Salmeterol (as xinafoate)
Normalized name: salmeterol (as xinafoate)
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Beta-agonist, LABA, pMDI
Study: NCT01212523
Drug: propofol and isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC
Study: NCT02012920
Drug: Seviteronel: given orally once daily in 28 day cycles
DrugBank: Seviteronel (DB12275)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01190293
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients (previously on an efavirenz-based therapy) will be administered maraviroc at 600mg twice-daily for 2 weeks.
Study: NCT02607319
Drug: Bemiparin sodium
Normalized name: bemiparin sodium
DrugBank: Bemiparin (DB09258)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.
Study: NCT01432171
Drug: Lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00482521
Drug: CC-4047
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period. Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined.
Study: NCT04289805
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: letrozole is orally administered (5mg/d) from cycle day 2-3 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist.
Study: NCT00826930
Drug: Trans Sodium Crocetinate (TSC)
Normalized name: trans-crocetin
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.
Study: NCT05278728
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200,400,600 or 800mg weekly until progression or AEs
Study: NCT05278728
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
Study: NCT00788125
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00788125
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03423667
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (1200 mg) administered twice a day during 5 days
Study: NCT00788125
Drug: etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00788125
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04076059
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT04303988
Drug: SHR-1316
Normalized name: Immunoglobulin G4 (52-glycine, 57-phenylalanine, 227-proline, 233-alanine, 234-alanine, 446-alanine), anti-(human programmed death-ligand 1) (human-mus musculus monoclonal SHR-1316 .gamma.4-chain) fusion protein with peptide linker ((ggggs)4g) fusion protein with 20-136-type II transforming growth factor .beta. receptor (human isoform 1), disulfide with (85-glutamic acid) human-mus musculus monoclonal SHR-1316 .kappa.-chain, dimer
DrugBank: Retlirafusp alfa (DB17517)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT04303988
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV
Study: NCT04303988
Drug: Cisplatin/Carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT03134755
Drug: Inhaled corticosteroid (mometasone)
Normalized name: mometasone Inhalant Product
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators are not measuring the effect of the intervention (ICS), but rather the effect of stress (which is not being intervened on), and this is thus an observational study. The ICS is given to children with asthma in whom an ICS is clinically indicated
Study: NCT03308201
Drug: Hemay022+exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part one: Hemay022 tablets will be taken orally once daily in doses of 200mg, 300mg,400mg or 500mg for 28 days in combination with exemestane.~Part two: Hemay022 tablets combination with exemestane.
Study: NCT00020345
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04790448
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Route of administration: Intravenous
Study: NCT04790448
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Route of administration: Intravenous
Study: NCT04790448
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Route of administration: Oral
Study: NCT02146430
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 150 mg capsule for oral administration
Study: NCT03308201
Drug: Hemay022+letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part two: Hemay022 combination with letrozole.
Study: NCT03308201
Drug: Hemay022+ fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Part two: Hemay022 combination with fulvestrant.
Study: NCT04625725
Drug: AZD7442
Normalized name: AZD7442
DrugBank: AZD7442 (DB15787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~* Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366
Study: NCT04029480
Drug: Ertugliflozin 5 mg
Normalized name: ertugliflozin 5 MG
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertugliflozin 5 mg, oral, 1 tablet QD
Study: NCT04029480
Drug: Ertugliflozin 15 mg
Normalized name: ertugliflozin 15 MG
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertugliflozin 15 mg, oral, 1 tablet QD
Study: NCT04029480
Drug: Placebo to ertugliflozin 15 mg
Normalized name: ertugliflozin 15 MG
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo to ertugliflozin 15 mg, oral, 1 tablet QD
Study: NCT04029480
Drug: Placebo to ertugliflozin 5 mg
Normalized name: ertugliflozin 5 MG
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo to ertugliflozin 5 mg, oral, 1 tablet QD
Study: NCT04029480
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive stable dose of background metformin.
Study: NCT02677896
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT02315690
Drug: dihydroartemisinin-piperaquine (DHAp)
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
Study: NCT01581788
Drug: Divalproex Sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex Sodium ER Tablets, 500 mg
Study: NCT03646318
Drug: Ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of 0.75 ug/kg/min is a dose that has been used frequently in critically ill patients. The concentration of the study drug infusion will be 40 mg/40 ml glucose 5%. The maximum dose however will be 4.5 mg per hour for patients with a weight more than 100 kg. The pre-filled 50 ml syringes will be filled with 40 ml of a solution containing 40 mg ketanserin or 0 mg ketanserin in glucose 5%.~The minimum number of ketanserin vials (2 ml with 5 mg/ml) that are needed is 240 (40 mg = 4 vials per patient). Duration of intervention: 8 hours
Study: NCT00261144
Drug: Collagenase
Normalized name: Collagenase
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 0.58mg injection every two weeks for six weeks (total three 0.58mg injections)
Study: NCT01436032
Drug: N1539
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV
Study: NCT01436032
Drug: Ketorolac Tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT01894711
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with trastuzumab in HER2 positive patients
Study: NCT00117481
Drug: DR-2001a
Normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DR-2001a administered vaginally each month
Study: NCT00117481
Drug: DR-2001b
Normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DR-2001b administered vaginally each month
Study: NCT04233866
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04233866
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04233866
Drug: Liposomal Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04305145
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion
Study: NCT04305145
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion
Study: NCT04305145
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally
Study: NCT00316745
Drug: TS-1
Normalized name: CTS-1027
DrugBank: Gimeracil (DB09257)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1 Day1\~14, everyday P.O.(Day 15\~28 rest)
Study: NCT00316745
Drug: L-Plat
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin (85mg/m2) Day 1, 15
Study: NCT00316745
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1\~3 (48 hours) of each 28 day cycle.
Study: NCT01929096
Drug: Compound Edaravone Injection
Normalized name: edaravone Injection
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01929096
Drug: Edaravone Injection
Normalized name: edaravone Injection
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01768858
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen
Study: NCT00041808
Drug: MTC-DOX for Injection
Normalized name: MTC-DOX for Injection
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03312530
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cobimetinib will be administered as per the schedule specified in the respective arm.
Study: NCT03312530
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax will be administered as per the schedule specified in the respective arm.
Study: NCT03312530
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered as per the schedule specified in the respective arm.
Study: NCT04233866
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03093324
Drug: ALKS 8700
Normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03093324
Drug: Dimethyl Fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03627936
Drug: Lorcaserin manufactured at Zofingen
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorcaserin XR tablets manufactured at Zofingen.
Study: NCT03801876
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03801876
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03801876
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT03627936
Drug: Lorcaserin manufactured at Kawashima
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorcaserin XR tablets manufactured at Kawashima.
Study: NCT00162734
Drug: Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks
Normalized name: interferon alfacon-1
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02954081
Drug: Phase I: Fumaric acid esters. Phase II: Apremilast
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast
Study: NCT00354744
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Age based dosage: ≥ 1 year: 100 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV
Study: NCT00354744
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Age based dosage: ≥ 1 year: 1800 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV
Study: NCT04241276
Drug: ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 mg/m2 orally (in two divided doses) from days 1 to 15 of each cycle
Study: NCT04241276
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
Study: NCT04241276
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
Study: NCT02658825
Drug: JNJ-63623872 2400 milligram (mg)
Normalized name: JNJ-63623872
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.
Study: NCT02658825
Drug: JNJ-63623872 3000 mg
Normalized name: JNJ-63623872
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.
Study: NCT03188198
Drug: rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00354744
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage 50 mg/m2-max dose 100 mg/day.~Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.~Given IV
Study: NCT00354744
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and \< 3 years 0.05 mg/kg (max dose 2 mg), \< 1 year 0.025 mg/kg.~Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.~Given IV
Study: NCT02658825
Drug: JNJ-63623872
Normalized name: JNJ-63623872
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.
Study: NCT02658825
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.
Study: NCT02658825
Drug: Placebo (Matching with JNJ-63623872 2400 mg)
Normalized name: JNJ-63623872
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.
Study: NCT04518176
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 units by slow intravenous drip injection
Study: NCT00034866
Drug: Protease inhibitor tipranavir
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02658825
Drug: Placebo (Matching with JNJ-63623872 3000 mg)
Normalized name: JNJ-63623872
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.
Study: NCT02658825
Drug: Placebo (Matching with JNJ-63623872 Dose)
Normalized name: JNJ-63623872
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.
Study: NCT00728949
Drug: tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily 20 mg, oral
Study: NCT00728949
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily 1 mg, oral
Study: NCT00728949
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily 2.5 mg, oral